This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Lung Cancer Alliance Applauds New NCI Study Showing Lung Cancer Screening As Cost Effective As Other Common Health Screenings

WASHINGTON, June 25, 2013 /PRNewswire-USNewswire/ -- Today, Lung Cancer Alliance (LCA) applauded a long awaited cost-benefit analysis, presented at a meeting of the National Cancer Institute's Board of Scientific Advisors and National Cancer Advisory Board, which concluded that a CT lung cancer screening program based on NCI's lung cancer screening trial meets generally accepted criteria for cost-effectiveness of a screening test.

"This report is an important contribution to our ongoing efforts to ensure that those at high risk for lung cancer have access to responsible CT screening and  brings us closer to the day when this life-saving benefit will be fully integrated into our nation's healthcare," stated Lung Cancer Alliance President and CEO, Laurie Fenton Ambrose

This follow-on analysis of the economics of CT lung cancer screening comes after the NCI's National Lung Screening Trial (NLST) proved the mortality benefit of screening a high risk population in 2010. 

The NCI study is consistent with other research documenting the cost –benefit of CT lung screening. Lung Cancer Alliance, which along with Legacy for Health, commissioned the international actuarial firm Milliman, Inc., to conduct a similar cost benefit study that is currently pending peer-review publication.

Two previous actuarial analyses by Milliman, Inc., indicated that screening those at high risk has the potential to save up to 70,000 lives a year and demonstrated that it would cost less to insure as a covered benefit than mammography or other screening protocols.

Lung Cancer Alliance has been a strong proponent of responsible CT screening for lung cancer.  Last year, LCA released its " National Framework for Excellence in Lung Cancer Screening and Continuum of Care ," to ensure that responsible high quality screening is available to those at risk within a multi-disciplinary setting following best published practice guidelines. Community-based and academic medical centers nationwide have adopted the National Framework and are standardizing the screening practices.  

"We have learned important hard lessons from other cancer screening processes and how these scientific breakthroughs were transitioned into public health benefit," continued Fenton-Ambrose. "We need to be sure that CT screening is done right – right from the start – as screening is not a snapshot. It is a multidisciplinary process that if equitably deployed can save tens of thousands of lives each year needlessly lost to lung cancer. That is why the National Framework has been a priority for us since its establishment February 2012 – and will continue until CT screening is fully implemented within our nation's public health infrastructure."

ABOUT LUNG CANCER ALLIANCELung Cancer Alliance (LCA), www.lungcanceralliance.org, is committed to ending injustice and saving lives through an alliance of advocacy, education and support. LCA provides live, real time support, referral and information services for patients, their loved ones and those at risk for lung cancer; conducts national awareness campaigns; and advocates for multiple millions in public health dollars for lung cancer research.

Follow Lung Cancer Alliance on Facebook: www.facebook.com/lungcanceralliance and on Twitter @LCAorg.

MEDIA CONTACT Kay Cofrancesco Kay@lungcanceralliance.org302-571-5716

SOURCE Lung Cancer Alliance

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,598.20 -91.66 -0.52%
S&P 500 2,098.04 -5.80 -0.28%
NASDAQ 5,115.3820 -12.8990 -0.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs